BioGaia AB's Nomination Committee for the 2024 Annual General Meeting
BioGaia AB's Nomination Committee for the Annual General Meeting 2024 has been appointed based on the ownership structure as of June 30, 2023.
The Nomination Committee consists of:
Peter Rothschild, Chair of the Board BioGaia AB
Per-Erik Andersson, Annwall & Rothschild Investments AB
Jacob Sellman, EQT
Marianne Flink, AP4
Russell Champion, Premier Miton Investors
Shareholders who would like to submit proposals to the Nomination Committee can do so by e-mail to nominationcommittee@biogaia.comor by ordinary mail under the address BioGaia AB, Nomination Committee, Kungsbroplan 3A, 112 27 Stockholm.
The Annual General Meeting in BioGaia AB will be held on April 26, 2024, in Stockholm.
Follow us:
Subscribe to BioGaia press releases here (https://www.biogaia.com/press/subscribe-to-press-releases/)
LinkedIn here (https://www.linkedin.com/company/biogaia-ab/)
Contacts:
Peter Rothschild, Chairman of the Board
Email: pr@biogaia.se
Phone: +46 708 30 65 40
Caroline Mofors, Chief Legal Officer
Email: cam@biogaia.se
Phone: +46 733 60 48 59
About BioGaia
BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaia.com (https://www.biogaia.com/)